Enrollment Open for a Trial of Novel Drug-Chemo Combo for Lu

The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.

Related Keywords

California , United States , Canada , China , Ian Anderson , Maky Zanganeh , Team Summit , Providence Medical Foundation , Summit Therapeutics , Santa Rosa , Standard Treatment May Not Be Best , Mutant Lung , Lung Cancer , Clinical Trial Corner ,